Current Edition

Aduhelm (aducanumab)

Amid Aduhelm’s rocky launch, Biogen eyes large-scale layoffs

Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …

Continue Reading →
Aduhelm (aducanumab)

ARIA side effects surface in 40% of patients on Biogen’s Alzheimer’s drug Aduhelm

Biogen’s Alzheimer’s disease drug Aduhelm has endured a headache of a launch, largely due to lingering questions about its true clinical benefit and how the …

Continue Reading →
Aduhelm

Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trial

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …

Continue Reading →
Alzheimer's

Topeka man involved in Alzheimer’s clinical trial

About 5 years ago, Topeka man, Allen Davis started to experience symptoms of Alzheimer’s Disease and Dementia. Now he’s focused on one thing. “Hopefully it’s not getting …

Continue Reading →
Alzheimer's

High Point Company’s Alzheimer’s Drug Trial Fails

The drug was in development for close to two decades. Experts say that without new drugs, Alzheimer’s efforts will need to focus on prevention. High …

Continue Reading →